Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-26 @ 1:11 AM
Study NCT ID:
NCT03528694
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-25
First Post:
2018-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-14
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2028-10-03
Completion Date Type:
ESTIMATED
First Submit Date:
2018-02-28
First Submit QC Date:
None
Study First Post Date:
2018-05-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-24
Last Update Post Date:
2025-11-25
Last Update Post Date Type:
ESTIMATED